Finance
UK's Hikma Pharmaceuticals Keeps 2026 Outlook, Confident in Managing Mideast War Costs
Published by Global Banking & Finance Review®
Posted on April 23, 2026
2 min readLast updated: April 23, 2026
Add as preferred source on Google
Quick Summary
Hikma Pharmaceuticals reaffirmed its 2026 guidance, despite Middle East war‑related shipping, energy and insurance cost pressures. Confident in absorbing these expenses, strong demand and new product launches across the US, France, Germany and MENA underpin a robust start to the year.
Hikma Pharmaceuticals Confident on 2026 Outlook Despite Mideast War Costs
Hikma Pharmaceuticals 2026 Guidance and Market Performance
Impact of Middle East War on Costs
April 23 (Reuters) - Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that while it has faced some pressure on shipping, energy, and insurance costs due to the Middle East war, it was confident it could absorb the higher expenses.
Strong Start to the Year and Market Expansion
The British drugmaker said it had a robust start to the year, driven by strong demand for its existing offerings and new launches in major markets, including the United States, France, and Germany.
CEO Leadership and Investor Sentiment
The update is a win for CEO Said Darwazah and provides some relief for investors worried over Hikma's recovery after persistent weakness in Hikma's injectables unit and delays at a key U.S. manufacturing site in Ohio forced the drugmaker to scrap its medium‑term targets in February.
Middle East Market and Supply Chain Management
Hikma said that demand in the Middle East, a key market for the firm, was "robust," and that it continues to maintain sufficient inventory levels to mitigate potential supply chain disruptions from the Iran war.
Revenue Contribution from MENA Region
Hikma sells its own-branded generics and licensed products across the Middle East and North Africa (MENA), which account for about a third of its core revenue and form the company's second-biggest market after North America. Its operations span over a dozen countries in MENA, including Iraq, Lebanon, Jordan, the UAE, and Saudi Arabia.
Financial Outlook and Business Focus
2026 Revenue and Profit Expectations
Hikma continues to expect group revenue to grow in the range of 2% to 4% and operating profit to be in the range of $720 million to $770 million for the year ending December 2026, with revenue growth of low single digits in the biggest injectables business.
Strategic Shift: Closing 503B Compounding Business
Focus on Core Operations
The company also said that it was closing down its 503B compounding business to focus on core operations. In the U.S., 503B compounding businesses manufacture bulk medicines for hospitals and clinics, not for individual patients, under the Food and Drug Administration's oversight.
(Reporting by Neeshita Beura and Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich)
Key Takeaways
- •Hikma maintained its 2026 outlook: group revenue growth of 2–4% and core operating profit of $720–770 million, despite cost headwinds from the Middle East conflict
- •Strong early‑year performance driven by demand for existing products and new launches in key markets: the US, France, Germany and MENA
- •MENA remains vital—accounting for about a third of core revenue—and Hikma says demand there is robust, with sufficient inventory to offset potential Iran‑related supply disruptions
Frequently Asked Questions about UK's Hikma Pharmaceuticals keeps 2026 outlook, confident in managing Mideast war costs
1What is Hikma Pharmaceuticals' financial outlook for 2026?
Hikma expects group revenue to grow 2-4% and operating profit to reach $720-$770 million by the end of 2026.
2How is the Middle East war affecting Hikma Pharmaceuticals?
The conflict has raised shipping, energy, and insurance costs, but Hikma says it can absorb these expenses and maintain sufficient inventory.
3Which regions are significant markets for Hikma Pharmaceuticals?
North America is Hikma's largest market, with the Middle East and North Africa (MENA) following as the second-biggest revenue source.
4What business segment is Hikma Pharmaceuticals shutting down?
Hikma is closing its 503B compounding business in the United States to focus on core operations.
5What are investors concerned about regarding Hikma's performance?
Investors have been worried about weakness in the injectables unit and delays at the Ohio manufacturing site.
